Carvedilol plus NUCs for compensated HBV-cirrhosis patients under virological suppression: a randomised, open-label trial.
The American journal of gastroenterology（2023）
摘要
The overall results did not show statistically significant differences between the added carvedilol strategy and NUCs monotherapy in preventing EVs progression in virologically suppressed HBV-cirrhosis patients. However, the carvedilol-added approach might offer improved outcomes specifically for patients with medium EVs (NCT03736265).
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要